Expression And Clinical Significances Of TCF4 And E-cadherin In Ovarian Tumor

Objective Testing the expression of TCF4 and E-cadherin in ovarian benign and malignant tumors, and analyze its clinical significance,Through the statistical analysis, providing the basis.for the specific marker for ovarian cancer metastasis and molecular targeted therapy drugs.Methods Immunohistochemistry was used to detect the expression of E-cadherin and TCF4 in 19 cases of ovarian benign cystadenomas,19 cases of borderline cystadenomas and 50 cases of ovarian cancer. Using SPSS 16.0 statistical analysis software for data statistics of border ovarian benign tumors, ovarian tumors and ovarian cancer tissue samples TCF4 and E-cadherin immunohistochemical results after scoring two independent samples t-test analysis TCF4 and E-cadherin differences expressed in ovarian benign and malignant tumor.Using protein in ovarian cancer immunohistochemical score cancer patients will be two groups, thus inspection analysis the relationship between the expression of TCF4 and E-cadherin and clinicopathological characteristics of patients with ovarian cancer.Results1. The expression of TCF4 and E-cadherin in benign cystadenomas, borderline cystadenomas and ovarian cancer. E-cadherin express in membrane of the epithelial cell. E-cadherin is strong positive expression in benign cystadenomas, that in borderline cystadenomas is positive expression, but almost no expression in ovarian cancer.TCF4 express parts in the cytoplasm, a strong positive expression in ovarian cancer, almost no expression in ovarian benign cystic adenoma, positive expression in borderline cystadenomas.TCF4 and E-cadherin express the differences of expression in ovarian benign and malignant tumors2. Immunohistochemical staining was scored which showed the expression of TCF4 in ovarian cancer, borderline cystadenomas was higher than benign cystadenomas(P< 0.05), the positive rate of TCF4 was 76%,63.2% and 31.6%, respectively. The positive rate of E-cadherin in benign cystadenomas, borderline cystadenomas, serous carcinoma was 78.9%,52.6% and 36%, respectively. The expression of E-cadherin in ovarian serous carcinoma and borderline cystadenomas was obviously lower than that of benign cystadenoma tissues (P<0.05). E-cadherin in ovarian benign and ovarian cancer, the expression showed a trend of decline.TCF4 expressed in ovarian benign and ovarian cancer, increasing trend.3. The expression of E-cadherin and TCF4 had nothing to do with the ovarian cancer patients’age (P>0.05). The expression of TCF4 was associated with ovarian cancer pathology classification, FIGO stage (P<0.05).Conclusions TCF4 expressed in ovarian cancer was higher than that in borderline cystadenomas and benign cystadenomas, at the same time,it was a positive correlation with the pathology classification and FIGO classification. E-cadherin expressed in ovarian cancer is lower than that in borderline cystadenomas and benign cystadenomas, at the same time,it was a negative correlation with the pathology classification and FIGO classification.